कोशिश गोल्ड - मुक्त
Al compass: Transforming pharma commercialisation
Express Pharma
|October 2025
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations

While much of the spotlight has been on AI's role in drug discovery, its influence is no longer confined to the laboratory. Discovery has often been described as the beating heart of any pharma company, where AI strengthens and accelerates critical breakthroughs. But if discovery is the heart, commercialisation is the network of nerves and veins. It is here that AI is fast becoming the compass, guiding companies in India and across the world toward more efficient, responsive, and innovative ways of bringing medicines to market and smoothing the business part of it.
As global healthcare landscapes become increasingly competitive and patient expectations evolve, the ability to leverage AI across commercial functions is no longer optional. From demand forecasting and inventory optimisation to personalised marketing and dynamic pricing, pharma companies are beginning to use AI to make decisions faster, anticipate market shifts, and tailor outreach to diverse stakeholders.
By bridging the gap between scientific innovation and business execution, AI is reshaping operations and enabling smarter, more agile, and scalable commercial strategies. The key question now is which companies are taking note and actively turning this potential into action?
Shifting gears with AI
Early signs suggest the momentum is building. An EY-OPPI survey shows that 79 per cent of pharma CXOs view AI and machine learning as central to growth. Indian organisations expect generative AI to transform their business within the next three years, driven by pressure from both internal and external stakeholders to accelerate adoption.
यह कहानी Express Pharma के October 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Express Pharma से और कहानियाँ

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size